{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:35:41Z","timestamp":1793136941389,"version":"4.5.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jaad.2026.08.072","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:21:44Z","timestamp":1787584904000},"page":"1320-1321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Highlights from JAAD Reviews: Skin in the Game: Dermatologic and Medicolegal Aspects of Glucagon-Like Peptide-1 Receptor Agonists"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-9304","authenticated-orcid":false,"given":"Shari R.","family":"Lipner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2026.08.072_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jdrv.2025.04.009","article-title":"Impact of glucagon-like peptide-1 receptor agonists on cutaneous events: a systematic review and meta-analysis","volume":"5","author":"Yu","year":"2025","journal-title":"JAAD Reviews"},{"key":"10.1016\/j.jaad.2026.08.072_bib2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jdrv.2026.07.002","article-title":"Glucagon-like peptide-1 receptor agonists and hair loss: current evidence and potential mechanisms","volume":"9","author":"Spindler","year":"2026","journal-title":"JAAD Reviews"},{"key":"10.1016\/j.jaad.2026.08.072_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jdrv.2026.06.001","article-title":"Dermatological adverse effects associated with the use of GLP-1 receptor agonists: a literature review","volume":"9","author":"Viquez Burboa","year":"2026","journal-title":"JAAD Reviews"},{"key":"10.1016\/j.jaad.2026.08.072_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2026.04.2020","article-title":"Sexual function is missing from the adverse-effect map of GLP-1 receptor agonists in dermatology","author":"Grimolizzi","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.08.072_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2026.06.018","article-title":"Evolving medicolegal liability patterns in GLP-1 receptor agonist prescribing","author":"Barnawi","year":"2026","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226033931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226033931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:28:10Z","timestamp":1793136490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226033931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0190962226033931"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.08.072","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highlights from JAAD Reviews: Skin in the Game: Dermatologic and Medicolegal Aspects of Glucagon-Like Peptide-1 Receptor Agonists","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.08.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}